血必净对脓毒性休克患者炎症反应及预后的影响
该研究为前瞻性随机对照研究,纳入2019年1月至12月郑州大学第一附属医院重症医学科收治的80例脓毒性休克患者,随机分为血必净组和对照组各40例,两组均按脓毒性休克诊治指南采取综合治疗措施,血必净组在此基础上给予血必净注射液100 mL静脉滴注、每日2次、疗程7天。结果显示血必净组第7天IL-6和HBP、第10天PCT、CRP、IL-6和HBP较对照组显著降低,机械通气时间和ICU停留时间显著缩短、总住院费用显著减少,但28天病死率和总住院时间无显著差异。Logistic回归显示CRP、IL-6和APACHEⅡ评分是影响预后的独立危险因素。
要点
- 脓毒性休克患者在指南综合治疗基础上加用血必净注射液100 mL静脉滴注、每日2次、疗程7天,可降低第7天IL-6和HBP水平(均P<0.05)。
- 血必净组第10天PCT、CRP、IL-6、HBP均较对照组显著降低(均P<0.05)。
- 血必净组机械通气时间57.0(0,163.5)小时 vs 对照组168.0(24.0,282.0)小时,ICU停留时间8.80±4.15天 vs 17.13±7.05天,均显著缩短(P<0.05)。
- 血必净组总住院费用14.55±7.31万元 vs 对照组20.01±9.86万元,显著减少(P<0.05);28天病死率37.5% vs 35.0%、总住院时间13.05±8.44天 vs 18.30±9.59天,均无显著差异(P>0.05)。
- CRP(OR 1.007)、IL-6(OR 1.828)、APACHEⅡ评分(OR 1.229)是脓毒性休克患者预后的独立危险因素(均P<0.05)。
适用人群与场景
- 2019年1月至12月郑州大学第一附属医院重症医学科收治的脓毒性休克患者80例,随机分为血必净组和对照组各40例。
处置流程与药物剂量
- 两组均严格遵循脓毒性休克诊治指南采取抗脓毒症综合治疗措施。
- 血必净组在综合治疗基础上给予血必净注射液100 mL静脉滴注、每日2次、疗程7天。
研究设计与关键结果
- 研究类型为前瞻性随机对照研究,纳入80例脓毒性休克患者,血必净组与对照组各40例,两组性别、年龄、感染部位、APACHEⅡ评分和SOFA评分等基线资料无显著差异。
- 两组血清炎症因子均呈治疗后下降趋势;血必净组第7天IL-6为66.20(16.34,163.71)ng/L vs 对照组79.81(23.95,178.64)ng/L,HBP为95.59(45.23,157.37)ng/L vs 132.98(73.90,162.05)ng/L,均P<0.05。
- 血必净组第10天PCT为1.14(0.20,3.39)μg/L vs 对照组1.31(0.68,4.21)μg/L,CRP为66.32(19.46,115.81)mg/L vs 89.16(20.52,143.76)mg/L,IL-6为31.90(13.23,138.74)ng/L vs 166.30(42.75,288.10)ng/L,HBP为62.45(29.17,96.51)ng/L vs 112.33(58.70,143.96)ng/L,均P<0.05。
- 血必净组机械通气时间57.0(0,163.5)小时 vs 对照组168.0(24.0,282.0)小时,ICU停留时间8.80±4.15天 vs 17.13±7.05天,总住院费用14.55±7.31万元 vs 20.01±9.86万元,均P<0.05。
- 血必净组与对照组28天病死率37.5% vs 35.0%、总住院时间13.05±8.44天 vs 18.30±9.59天,均无显著差异(P>0.05)。
- 单因素分析显示WBC、NEU%、CRP、乳酸、APACHEⅡ评分、IL-6、HBP是影响预后的因素;Logistic回归显示CRP(OR 1.007)、IL-6(OR 1.828)、APACHEⅡ评分(OR 1.229)为预后独立危险因素(均P<0.05)。
证据类型、等级与局限
- 证据类型为前瞻性随机对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,联合血必净治疗脓毒性休克可在一定程度上降低机体炎症反应,从而减少机械通气时间、缩短ICU停留时间并降低总住院费用,但不能降低脓毒性休克患者的28天病死率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To study the effect of Xuebijing on inflammatory response and prognosis in patients with septic shock.
METHODS: A prospective randomized controlled study was conducted. Eighty septic shock patients admitted to department of critical care medicine of the First Affiliated Hospital of Zhengzhou University from January to December in 2019 were enrolled. The enrolled patients were divided into Xuebijing group and control group by randomized number table method, with 40 cases in each group. Both groups were strictly followed the guidelines for the diagnosis and treatment of septic shock to take comprehensive treatment measures against sepsis. On this basis, Xuebijing group received intravenous 100 mL Xuebijing injection twice a day for 7 days. Baseline data of enrolled patients were recorded. The levels of interleukin-6 (IL-6), procalcitonin (PCT), C-reactive protein (CRP) and heparin binding protein (HBP) were measured before treatment and 3, 7 and 10 days after treatment. Mechanical ventilation time, the length of intensive care unit (ICU) stay, total hospitalization time and 28-day mortality were recorded. The differences of every indicator between the two groups were compared. Independent risk factors affecting patient prognosis were analyzed by binary Logistic regression.
RESULTS: (1) There was no significant difference in baseline data such as gender, age, infection site, acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure score (SOFA) between the two groups. (2) The levels of serum inflammatory factors in both groups showed a decreasing trend after treatment. Compared with the control group, IL-6 and HBP in the Xuebijing group significantly decreased on day 7 [IL-6 (ng/L): 66.20 (16.34, 163.71) vs. 79.81 (23.95, 178.64), HBP (ng/L): 95.59 (45.23, 157.37) vs. 132.98 (73.90, 162.05), both P < 0.05]; on day 10, PCT, CRP, IL-6 and HBP significantly decreased [PCT (μg/L): 1.14 (0.20, 3.39) vs. 1.31 (0.68, 4.21), CRP (mg/L): 66.32 (19.46, 115.81) vs. 89.16 (20.52, 143.76), IL-6 (ng/L): 31.90 (13.23, 138.74) vs. 166.30 (42.75, 288.10), HBP (ng/L): 62.45 (29.17, 96.51) vs. 112.33 (58.70, 143.96), all P < 0.05]. (3) Compared with the control group, mechanical ventilation time and the length of ICU stay were significantly shortened and the total hospitalization expenses were significantly reduced in Xuebijing group [mechanical ventilation time (hours): 57.0 (0, 163.5) vs. 168.0 (24.0, 282.0), the length of ICU stay (days): 8.80±4.15 vs. 17.13±7.05, the total hospitalization expenses (ten thousand yuan): 14.55±7.31 vs. 20.01±9.86, all P < 0.05]. There was no significant difference in 28-day mortality and the total hospitalization time [28-day mortality: 37.5% vs. 35.0%, the total hospitalization time (days): 13.05±8.44 vs. 18.30±9.59, both P > 0.05]. (4) Patients were divided into death and survival groups according to the prognosis, and univariate analysis showed that white blood cell (WBC), neutrophil percentage (NEU%), CRP, lactic acid (Lac), APACHE II score, IL-6, HBP were the factors influencing the prognosis of patients. The above indicators were further analyzed by Logistic regression, which showed that CRP, IL-6, and APACHE II score were independent risk factors for prognosis [odds ratio (OR) was 1.007, 1.828, 1.229, all P < 0.05].
CONCLUSIONS: Combined with Xuebijing to treat septic shock can reduce the body's inflammatory response to a certain extent, thereby reducing the time of mechanical ventilation, shortening the stay of ICU and reducing the total cost of hospitalization. But it cannot reduce the 28-day mortality of patients with septic shock.
参考来源
- Sun R, Liang M, Yang H, et al. [Effect of Xuebijing on inflammatory response and prognosis in patients with septic shock]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 32527353. doi:10.3760/cma.j.cn121430-20200401-00333
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。